Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial
Ist Teil von
Vaccine, 2013-12, Vol.31 (51), p.6136-6143
Ort / Verlag
Kidlington: Elsevier Ltd
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
Highlights • We evaluated safety of an investigational HSV vaccine in girls aged 10–17 years. • Serious adverse events (SAEs) were evaluated over 12 months (primary objective). • SAE rates did not differ significantly between the HSV vaccine and control groups. • A clinically acceptable safety profile was observed for the HSV vaccine overall. • The HSV vaccine was immunogenic in this study group, regardless of HSV serostatus.